menu
    • menu

    Find Olaparib manufacturers, exporters & distributors on PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Olaparib

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Olaparib

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    49

    API Suppliers

    API Suppliers

    17

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    5

    EU WC

    EU WC

    6

    KDMF

    KDMF

    13

    NDC API

    NDC API

    0

    VMF

    NDC API

    29

    Listed Suppliers

    Other Suppliers

    39INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    13

    Others

    FINISHED DOSAGE FORMULATIONS

    50

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    12

    Europe

    Europe

    2

    Canada

    Canada

    22

    Australia

    Australia

    2

    South Africa

    South Africa

    7

    Listed Dossiers

    Listed Dossiers

    320DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    111RELATED EXCIPIENT COMPANIES

    216EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    117

    US Patents

    10

    US Exclusivities

    16

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 7,247

    GLOBAL SALES INFORMATION

    US Medicaid

    487,431,793

    Annual Reports

    20,976

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    9

    API

    5

    FDF

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    276

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281
    Molecular Formula
    C24H23FN4O3
    Molecular Weight
    434.5  g/mol
    InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    FDA UNII
    WOH1JD9AR8
    Olaparib
    Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
    Olaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.
    1 2D Structure

    Olaparib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
    2.1.2 InChI
    InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
    2.1.3 InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
    2.2 Other Identifiers
    2.2.1 UNII
    WOH1JD9AR8
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Azd 2281

    2. Azd-2281

    3. Azd221

    4. Azd2281

    5. Lynparza

    2.3.2 Depositor-Supplied Synonyms

    1. 763113-22-0

    2. Lynparza

    3. Azd2281

    4. Azd-2281

    5. Ku-0059436

    6. Azd 2281

    7. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine

    8. Olaparib (azd-2281)

    9. 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    10. Ku-59436

    11. Olaparib (azd2281, Ku-0059436)

    12. 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2h-phthalazin-1-one

    13. Az2281

    14. Mfcd13185161

    15. Woh1jd9ar8

    16. Nsc-747856

    17. C24h23fn4o3

    18. Chebi:83766

    19. 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one

    20. 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one

    21. Az-2281

    22. Keylynk-010 Component Olaparib

    23. Ku59436

    24. Olaparib Component Of Keylynk-010

    25. Olaparib [inn]

    26. Olaparib Cpd

    27. Olaparib (azd2281; Ku-0059436)

    28. Olaparib [usan:inn]

    29. Unii-woh1jd9ar8

    30. Olaparib (azd2281)

    31. Acylpiperazine Analogue, 47

    32. Olaparibum

    33. Azd221

    34. 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2h)-one

    35. Olaparib- Bio-x

    36. Lynparza (tn)

    37. 09l

    38. 4-((3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    39. 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    40. 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2h)-one

    41. Ku 59436

    42. Olaparib [usan]

    43. Olaparib [jan]

    44. Ku0059436

    45. Olaparib [mi]

    46. Olaparib [vandf]

    47. Olaparib - Azd2281

    48. Olaparib [mart.]

    49. Olaparib [who-dd]

    50. Azd-2281 (olaparib)

    51. Olaparib (jan/usan/inn)

    52. Mls006010185

    53. Schembl426568

    54. Olaparib [orange Book]

    55. Chembl521686

    56. Gtpl7519

    57. Bdbm27566

    58. Dtxsid60917988

    59. Ex-a002

    60. Bcpp000360

    61. Hms3295i09

    62. Hms3426c03

    63. Hms3654g13

    64. Hms3746k07

    65. Hms3870h03

    66. Amy10295

    67. Bcp01872

    68. 763113-22-0, Lynparza,

    69. Nsc747856

    70. Nsc753686

    71. S1060

    72. Zinc40430143

    73. Akos005145764

    74. Ac-7939

    75. Bcp9000363

    76. Ccg-264799

    77. Cs-0075

    78. Db09074

    79. Ex-7210

    80. Nsc 747856

    81. Nsc-753686

    82. Sb14617

    83. Ss-4573

    84. Azd2281,olaparib, Ku-0059436

    85. Ncgc00238451-01

    86. Ncgc00238451-02

    87. Ncgc00238451-08

    88. Ncgc00238451-09

    89. Ncgc00238451-11

    90. 4-[(3-{[4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2h)-one

    91. 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2h)-phthalazinone

    92. Bo164169

    93. Hy-10162

    94. Smr004701291

    95. Sy040527

    96. Olaparib(azd2281,kudosku-0059436)

    97. A9666

    98. Bb 0260909

    99. Ft-0651458

    100. Ku 0059436

    101. Sw218142-2

    102. Ec-000.2324

    103. D09730

    104. J-503540

    105. Q7083106

    106. Brd-k02113016-001-08-9

    107. Brd-k02113016-001-09-7

    108. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine

    109. 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    110. (2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    111. 1(2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    112. 1021843-02-6

    113. 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one

    114. Piperazine, 1-(cyclopropylcarbonyl)-4-(5-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)-2-fluorobenzoyl)-

    2.4 Create Date
    2008-02-11
    3 Chemical and Physical Properties
    Molecular Weight 434.5 g/mol
    Molecular Formula C24H23FN4O3
    XLogP31.9
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count4
    Exact Mass434.17541877 g/mol
    Monoisotopic Mass434.17541877 g/mol
    Topological Polar Surface Area82.1 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity790
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of: - Ovarian cancer, in which the medication is intended for [a] the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy, or [b] for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib. - Breast cancer, in which the medication is intended for use in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib.

    FDA Label

    * Ovarian cancer :

    Lynparza is indicated as monotherapy for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

    - maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

    Lynparza in combination with bevacizumab is indicated for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5. 1).

    * Breast cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer . Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5. 1).

    Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

    * Adenocarcinoma of the pancreas:

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

    * Prostate cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum based chemotherapy.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Poly(ADP-ribose) Polymerase Inhibitors

    Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    OLAPARIB
    5.3.2 FDA UNII
    WOH1JD9AR8
    5.3.3 Pharmacological Classes
    Poly(ADP-Ribose) Polymerase Inhibitors [MoA]; Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
    5.4 ATC Code

    L01XK01

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XK - Poly (adp-ribose) polymerase (parp) inhibitors

    L01XK01 - Olaparib

    5.5 Absorption, Distribution and Excretion

    Absorption

    Following oral administration, the absorption of olaparib is very rapid and can reach a peak concentration ranging between 4.7 and 9.1 mcg/ml after 1-3 hours. The reported AUC of olaparib after a dose of 200 mg is of 25.8 mcg.h/L and this AUC can be increased by 26% with constant administration. The consumption of a high-fat diet with olaparib can only decrease the tmax but do not have an effect in the peak concentration.

    Route of Elimination

    From the administered dose, approximately 86% of the administered dose is recovered after 7 days from which 44% is found in the urine and 42% is obtained in feces.

    Volume of Distribution

    After administration of a dose of 100 mg/kg, the reported volume of distribution was of 40.3 L.

    Clearance

    The total clearance of olaparib was reported to be 4.6 L/h.

    5.6 Metabolism/Metabolites

    Olaparib is extensively metabolized in the liver by the action of CYP3A isoenzymes. From the administered dose, the unchanged form of olaparib accounted for 70% of the circulating dose and it was considered the major component in urine and feces. The metabolic pathway of olaparib is mainly attributable to oxidation reactions with subsequent glucuronide and sulfate conjugation. However, the over 20 metabolites found in plasma, urine, and feces represented a minor portion of the administered dose. The major circulating metabolites were represented by the mono-oxygenated form and the piperazin-3-ol form.

    5.7 Biological Half-Life

    The reported elimination half-life ranges between 5 to 11 hours.

    5.8 Mechanism of Action

    Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

    Listed Suppliers

    read-more
    read-more

    01

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

    Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Kinsy SL

    Spain
    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothReliable Spanish CDMO Delivering High-Quality APIs and Intermediates with Excellence, Flexibility, and Regulatory Compliance.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Kinsy, an independent CDMO in Spain, offers over 30 years of expertise in developing and manufacturing advanced pharmaceutical intermediates and APIs. We provide innovative route d...

    Kinsy, an independent CDMO in Spain, offers over 30 years of expertise in developing and manufacturing advanced pharmaceutical intermediates and APIs. We provide innovative route development, analytical method optimization, pilot plant scale-up, and clinical-phase production with advanced purification techniques. Our services include process validation, commercial-scale manufacturing (>100 MT/year), and regulatory support (DMF, CEP, REACH). ISO 9001-certified and operating under cGMP standards audited by AEMPS, we are a trusted partner to leading global pharmaceutical companies.
    Kinsy SL Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Axplora

    Germany
    arrow
    NLS Days
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAxplora is your partner of choice for complex APIs.

    Contact Supplier Contact Supplier
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    LGM Pharma

    U.S.A
    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

    LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Rochem International Inc

    U.S.A
    arrow
    CPhI WW Frankfurt
    Booth #12.0F117
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

    Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.
    Rochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Emay Pharmaceuticals

    India
    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEmay Pharmaceuticals is a GMP-certified API manufacturing company.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Emay Pharmaceuticals Pvt Ltd functions as the merchant export division of M/s. Bhavna Laboratories Pvt Ltd. As a GMP-approved API manufacturing company, we boast over three decades...

    Emay Pharmaceuticals Pvt Ltd functions as the merchant export division of M/s. Bhavna Laboratories Pvt Ltd. As a GMP-approved API manufacturing company, we boast over three decades of experience in exporting a wide array of Pharmaceutical and allied products, engaging in both manufacturing and export operations. Emay Pharmaceuticals Pvt Ltd comprises a team of seasoned professionals with extensive expertise in Human Health APIs and Veterinary Health APIs. Specializing in the trade of various raw materials for both Human and Veterinary medicine, Emay Pharmaceuticals Pvt Ltd is dedicated to providing quality products.
    Emay Pharmaceuticals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Aarti Pharmalabs

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...

    Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic & oncology products. It has 2 R&D centers & 3 cGMP plants successfully audited by the USFDA, EUGMP, EDQM, KFDA & COFEPRIS. It offers CDMO services for generic APIs & NCEs, intermediates & key building blocks.Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
    Aarti Industries Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Jinan Tantu Chemicals

    China
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

    Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Shanghai Minbiotech

    China
    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

    ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Lee Fine Chem

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Lee Fine Chem Private Limited specializes in Advanced Intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms. With a strong focus on quality and innovat...

    Lee Fine Chem Private Limited specializes in Advanced Intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms. With a strong focus on quality and innovation, we deliver high-performance pharmaceutical solutions to global markets. Our state-of-the-art facilities and expert team ensure compliance, consistency, and excellence at every stage of development and production. Trust Lee Fine Chem for reliable, efficient, and cutting-edge pharmaceutical products.
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642357800,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12500","totalValueFC":"36902.6","currency":"USD","unitRateINR":916333.33333333337,"date":"17-Jan-2022","totalValueINR":"2749000","totalValueInUsd":"36902.6","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"7529366","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652898600,"product":"OLAPARIB (TAX INV NO: 1905225024 DT:30.0","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"SKISPRING INTERTRADE S A","customerCountry":"URUGUAY","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"9900","totalValueFC":"9354.9","currency":"USD","unitRateINR":723000,"date":"19-May-2022","totalValueINR":"723000","totalValueInUsd":"9354.9","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"1495921","productDescription":"API","marketType":"","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653589800,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"AMMAN","customer":"UNDISCLOSED","customerCountry":"JORDAN","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"9000","totalValueFC":"22177.4","currency":"USD","unitRateINR":685600,"date":"27-May-2022","totalValueINR":"1714000","totalValueInUsd":"22177.4","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"1704900","productDescription":"API","marketType":"","country":"JORDAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1654453800,"product":"OLAPARIB (PHARMACEUTICAL RAW MATERIAL)(I","address":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (","city":"MUMBAI","supplier":"AARTI INDUSTRIES LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"GENVION CORP","customerCountry":"CANADA","quantity":"95.00","actualQuantity":"95","unit":"KGS","unitRateFc":"3960","totalValueFC":"368440.6","currency":"USD","unitRateINR":302568.42105263157,"date":"06-Jun-2022","totalValueINR":"28744000","totalValueInUsd":"368440.6","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"1933031","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB HOT MELT EXTRUDES- BATCH NO.024","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"2350.8","totalValueFC":"1123","currency":"USD","unitRateINR":180000,"date":"08-Sep-2022","totalValueINR":"90000","totalValueInUsd":"1123","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668018600,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"10500","totalValueFC":"52577.6","currency":"USD","unitRateINR":858200,"date":"10-Nov-2022","totalValueINR":"4291000","totalValueInUsd":"52577.6","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"5376603","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670524200,"product":"OLAPARIB DCG 25% W\/W (OTHER) (LUT (ARN)","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SINGAPORE","customer":"ALCAPTLT","customerCountry":"SINGAPORE","quantity":"0.70","actualQuantity":"700","unit":"GMS","unitRateFc":"4.9","totalValueFC":"3385.7","currency":"EURO","unitRateINR":398.57142857142856,"date":"09-Dec-2022","totalValueINR":"279000","totalValueInUsd":"3385.7","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"6032492","productDescription":"API","marketType":"","country":"SINGAPORE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671042600,"product":"OLAPARIB API","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"31.00","actualQuantity":"31","unit":"KGS","unitRateFc":"6140.5","totalValueFC":"185490.6","currency":"USD","unitRateINR":493083.38709677418,"date":"15-Dec-2022","totalValueINR":"15285585","totalValueInUsd":"185490.6","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29337990","bill_no":"4007767","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677522600,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"0.29","actualQuantity":"0.29","unit":"KGS","unitRateFc":"7000","totalValueFC":"1913.1","currency":"USD","unitRateINR":544827.58620689658,"date":"28-Feb-2023","totalValueINR":"158000","totalValueInUsd":"1913.1","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"8131098","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678905000,"product":"OLAPARIB API","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO LLC","customerCountry":"UNITED STATES","quantity":"79.00","actualQuantity":"79","unit":"KGS","unitRateFc":"6626.7","totalValueFC":"520327.4","currency":"USD","unitRateINR":541735.69620253169,"date":"16-Mar-2023","totalValueINR":"42797120","totalValueInUsd":"520327.4","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29337990","bill_no":"4001590","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689877800,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"10000","totalValueFC":"29517.1","currency":"USD","unitRateINR":808666.67700000003,"date":"21-Jul-2023","totalValueINR":"2426000.031","totalValueInUsd":"29517.1","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690137000,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"9540.7","totalValueFC":"18851.7","currency":"USD","unitRateINR":774707.5,"date":"24-Jul-2023","totalValueINR":"1549415","totalValueInUsd":"18851.7","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000441","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691519400,"product":"OLAPARIB BATCH NO;OLBB022001","address":"NA","city":"BANGALORE","supplier":"ACEBRIGHT INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"6000","totalValueFC":"8541.9","currency":"USD","unitRateINR":471721.614,"date":"09-Aug-2023","totalValueINR":"707582.421","totalValueInUsd":"8541.9","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NA, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691951400,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"8121.1","totalValueFC":"40146.5","currency":"USD","unitRateINR":665116.80000000005,"date":"14-Aug-2023","totalValueINR":"3325584","totalValueInUsd":"40146.5","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000512","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697653800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (API) OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"7.20","actualQuantity":"7.2","unit":"KGS","unitRateFc":"9000","totalValueFC":"63859.7","currency":"USD","unitRateINR":738194.44444444438,"date":"19-Oct-2023","totalValueINR":"5315000","totalValueInUsd":"63859.7","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"4760317","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702233000,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(API): OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4050","totalValueFC":"3964.3","currency":"USD","unitRateINR":330000,"date":"11-Dec-2023","totalValueINR":"330000","totalValueInUsd":"3964.3","indian_port":"Bombay Air","hs_no":"29331999","bill_no":"5955701","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706553000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BIOPROFARMA BAGO S A","customerCountry":"ARGENTINA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"21000","totalValueFC":"5993.8","currency":"USD","unitRateINR":1660516.6666666667,"date":"30-Jan-2024","totalValueINR":"498155","totalValueInUsd":"5993.8","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"7118633","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710873000,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)(PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"LISBON","customer":"UNDISCLOSED","customerCountry":"PORTUGAL","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"8000","totalValueFC":"9277","currency":"USD","unitRateINR":641939.05000000005,"date":"20-Mar-2024","totalValueINR":"770326.86","totalValueInUsd":"9277","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"8468505","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711564200,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"7986.7","totalValueFC":"39555.6","currency":"USD","unitRateINR":656906.80000000005,"date":"28-Mar-2024","totalValueINR":"3284534","totalValueInUsd":"39555.6","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29332990","bill_no":"4000236","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716575400,"product":"OLAPARIB IH (GST TAX INV.SI3624200796 DT: 30.04.2024)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"5359.7","currency":"EURO","unitRateINR":893500,"date":"25-May-2024","totalValueINR":"446750","totalValueInUsd":"5359.7","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"1152722","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719340200,"product":"OLAPARIB IH (GST TAX INV.SI3624200796 DT: 30.04.2024)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"5276.7","currency":"EURO","unitRateINR":881000,"date":"26-Jun-2024","totalValueINR":"440500","totalValueInUsd":"5276.7","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"1947978","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726770600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS ? (API) (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME ? OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"LISBON","customer":"UNDISCLOSED","customerCountry":"PORTUGAL","quantity":"5.50","actualQuantity":"5.5","unit":"KGS","unitRateFc":"8000","totalValueFC":"43268.4","currency":"USD","unitRateINR":659263.30545454554,"date":"20-Sep-2024","totalValueINR":"3625948.18","totalValueInUsd":"43268.4","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"4185472","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734978600,"product":"ACTIVE PHARMA INGREDIENTS (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME - OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"9500","totalValueFC":"46831.5","currency":"USD","unitRateINR":795844.54000000004,"date":"24-Dec-2024","totalValueINR":"3979222.7","totalValueInUsd":"46831.5","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"6711693","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739298600,"product":"(REWARD ITEM)(PHARMACEUTICAL ALLOPATHICRAW MATERIALOF PHARMACEUTICAL GRADE) OLAPARIB(TAX INV.VLS\/EXP\/32\/2024-25)","address":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA","city":"N\/A","supplier":"VANNSH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"PHARMA LORD PVT LTD","customerCountry":"PAKISTAN","quantity":"0.08","actualQuantity":"75","unit":"GMS","unitRateFc":"30","totalValueFC":"2183.5","currency":"USD","unitRateINR":2531.8464000000004,"date":"12-Feb-2025","totalValueINR":"189888.48","totalValueInUsd":"2183.5","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"8096709","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741717800,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5806","totalValueFC":"28856.5","currency":"USD","unitRateINR":499896.59999999998,"date":"12-Mar-2025","totalValueINR":"2499483","totalValueInUsd":"28856.5","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"8960086","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741717800,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5806","totalValueFC":"28856.5","currency":"USD","unitRateINR":499896.59999999998,"date":"12-Mar-2025","totalValueINR":"2499483","totalValueInUsd":"28856.5","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"8960096","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1743705000,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"3989.6","totalValueFC":"98922.6","currency":"USD","unitRateINR":338717.88880000002,"date":"04-Apr-2025","totalValueINR":"8467947.22","totalValueInUsd":"98922.6","indian_port":"Bombay Air","hs_no":"29333990","bill_no":"9667190","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1744309800,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"WELLCHEM GLOBAL CO LTD","customerCountry":"TAIWAN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"15000","totalValueFC":"14805.2","currency":"USD","unitRateINR":1267348,"date":"11-Apr-2025","totalValueINR":"1267348","totalValueInUsd":"14805.2","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"9879931","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1750876200,"product":"OLAPARIB (FORM-A)","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"APIIC MAHABOOBNAGAR","customer":"HETERO LABS LTD SEZ UNIT I","customerCountry":"INDIA","quantity":"110.00","actualQuantity":"110","unit":"KGS","unitRateFc":"2629","totalValueFC":"289277.4","currency":"USD","unitRateINR":225966.17554545452,"date":"26-Jun-2025","totalValueINR":"24856279.31","totalValueInUsd":"289277.4","indian_port":"SEZ\/Mahaboobnagar","hs_no":"29334900","bill_no":"3049118","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"SEZ\/Mahaboobnagar","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1752690600,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"3027.6","totalValueFC":"44588.3","currency":"USD","unitRateINR":255835.58000000002,"date":"17-Jul-2025","totalValueINR":"3837533.7","totalValueInUsd":"44588.3","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"3645974","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1754591400,"product":"OLAPARIB API(PHARMACEUTICAL RAW MATERIALS)(INV NO. PEX\/100503\/25-26 DT. 01.08.2025)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS LTD","supplierCountry":"INDIA","foreign_port":"WINNIPEG","customer":"TO ORDER","customerCountry":"CANADA","quantity":"42.04","actualQuantity":"42.04","unit":"KGS","unitRateFc":"2347","totalValueFC":"97965.3","currency":"USD","unitRateINR":203945.97454804947,"date":"08-Aug-2025","totalValueINR":"8573888.77","totalValueInUsd":"97965.3","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"4273964","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1755109800,"product":"OLAPARIB(PHARMACEUTICAL RAW MATERIAL)(INV NO. PEX\/100541\/25-26 DT. 13.08.2025)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS LTD","supplierCountry":"INDIA","foreign_port":"WINNIPEG","customer":"TO ORDER","customerCountry":"CANADA","quantity":"39.94","actualQuantity":"39.94","unit":"KGS","unitRateFc":"2347","totalValueFC":"92466.8","currency":"USD","unitRateINR":202620.54932398599,"date":"14-Aug-2025","totalValueINR":"8092664.74","totalValueInUsd":"92466.8","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"4444285","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655663400,"product":"LUT-65 OLAPARIB","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"NA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"32.50","actualQuantity":"32.5","unit":"KGS","unitRateFc":"7200","totalValueFC":"236803.6","currency":"USD","unitRateINR":"568440","date":"20-Jun-2022","totalValueINR":"18474300","totalValueInUsd":"236803.6","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"9190560","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669055400,"product":"OLAPARIB HOT MELT EXTRUDES (TEST LIC.NO. TL\/AZ\/22\/002757) FOR R & D PURPOSE NOT FOR SALE (FOC)","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"BIO DURO SUNDIA","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"15.64","actualQuantity":"15.64","unit":"KGS","unitRateFc":"2350.9","totalValueFC":"38489.4","currency":"USD","unitRateINR":"200845.3","date":"22-Nov-2022","totalValueINR":"3141220.12","totalValueInUsd":"38489.4","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"3422337","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694025000,"product":"OLAPARIB HOT MELT EXTRUDES. BATCH NO. 10000933. MFG. DATE 16\/08\/2023. MCN NO. 5000947","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR","city":"AHMEDABAD\/GUJRAT","supplier":"XXODUXX LLXX","supplierCountry":"UNITED STATES","foreign_port":"LOS ANGELES","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"31.00","actualQuantity":"31","unit":"KGS","unitRateFc":"2059.9","totalValueFC":"64581.8","currency":"USD","unitRateINR":"172929.6","date":"07-Sep-2023","totalValueINR":"5360818","totalValueInUsd":"64581.8","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29339990","bill_no":"1003720","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"LOS ANGELES","supplierAddress":"N\/A","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR"}]
    17-Jan-2022
    14-Aug-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    IMGN151 IV Safety & Disease Activity In Gynecologic Cancers ± Combination

    Details:

    IMGN151 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Genital Neoplasms, Female.


    Lead Product(s): IMGN151,Carboplatin,Olaparib,Bevacizumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody-drug Conjugate

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 17, 2025

    Abbvie Company Banner

    01

    AbbVie Inc

    U.S.A
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : IMGN151,Carboplatin,Olaparib,Bevacizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    IMGN151 IV Safety & Disease Activity In Gynecologic Cancers ± Combination

    Details : IMGN151 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Genital Neoplasms, Female.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    June 17, 2025

    Abbvie Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

    Details:

    (SYN818) is currently being evaluated in Phase I clinical studies for the treatment of Neoplasm Metastasis.


    Lead Product(s): SYN818,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 05, 2025

    blank

    02

    SynRx Therapeutics

    Country
    arrow
    FNCE
    Not Confirmed

    SynRx Therapeutics

    Country
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SYN818,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

    Details : (SYN818) is currently being evaluated in Phase I clinical studies for the treatment of Neoplasm Metastasis.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    September 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BR2022 vs BR2022-1 PK & Safety In Germline BRCA-Mutated Advanced Ovarian Cancer

    Details:

    Olaparib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Ovarian Neoplasms.


    Lead Product(s): Olaparib,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 16, 2025

    blank

    03

    Boryung Pharmaceutical Co., Ltd

    South Korea
    arrow
    FNCE
    Not Confirmed

    Boryung Pharmaceutical Co., Ltd

    South Korea
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    BR2022 vs BR2022-1 PK & Safety In Germline BRCA-Mutated Advanced Ovarian Cancer

    Details : Olaparib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Ovarian Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    July 16, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Investigating Idetrexed and Olaparib in Patients with Ovarian Cancer

    Details:

    Idetrexed is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Ovarian Neoplasms.


    Lead Product(s): Idetrexed,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Algok Bio Inc.

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 16, 2025

    blank

    04

    Institute of Cancer Research, United Kingdom

    Country
    arrow
    FNCE
    Not Confirmed

    Institute of Cancer Research, United Kingdom

    Country
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Idetrexed,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Algok Bio Inc.

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Investigating Idetrexed and Olaparib in Patients with Ovarian Cancer

    Details : Idetrexed is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Ovarian Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 16, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pathos AI Raises $365M Series D to Boost Oncology Drug Discovery via AI

    Details:

    The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.


    Lead Product(s): Pocenbrodib,Abiraterone Acetate,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: $365.0 million Upfront Cash: Undisclosed

    Deal Type: Series D Financing May 15, 2025

    blank

    05

    Pathos

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Pathos

    U.S.A
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pocenbrodib,Abiraterone Acetate,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : $365.0 million

    Deal Type : Series D Financing

    DEALS_DEV arrow-down

    Pathos AI Raises $365M Series D to Boost Oncology Drug Discovery via AI

    Details : The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    May 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Details:

    Sacituzumab Tirumotecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): Sacituzumab Tirumotecan,Pembrolizumab,Carboplatin,Paclitaxel,Doxorubicin Hydrochloride,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 13, 2025

    blank

    06

    Merck & Co

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sacituzumab Tirumotecan,Pembrolizumab,Carboplatin,Paclitaxel,Doxorubicin Hydrochloride,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-28...

    Details : Sacituzumab Tirumotecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    May 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patie...

    Details:

    IMNN-001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Ovarian Epithelial.


    Lead Product(s): IMNN-001,Paclitaxel,Carboplatin,Olaparib,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Cell & Gene Therapy

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 07, 2025

    blank

    07

    Imunon

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Imunon

    U.S.A
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : IMNN-001,Paclitaxel,Carboplatin,Olaparib,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard...

    Details : IMNN-001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Ovarian Epithelial.

    Product Name : Undisclosed

    Product Type : Cell & Gene Therapy

    Upfront Cash : Inapplicable

    April 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Details:

    FPI-2265 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.


    Lead Product(s): FPI-2265,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Radiolabeled Compound

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 04, 2025

    blank

    08

    Fusion Pharma

    Canada
    arrow
    FNCE
    Not Confirmed

    Fusion Pharma

    Canada
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FPI-2265,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate ...

    Details : FPI-2265 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

    Product Name : Undisclosed

    Product Type : Radiolabeled Compound

    Upfront Cash : Inapplicable

    April 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

    Details:

    Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.


    Lead Product(s): Pembrolizumab,Paclitaxel,Carboplatin,Doxorubicin Hydrochloride,Boserolimab,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 17, 2025

    blank

    09

    Merck & Co

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Paclitaxel,Carboplatin,Doxorubicin Hydrochloride,Boserolimab,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early...

    Details : Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    February 17, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment i...

    Details:

    Durvalumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometrial Neoplasms.


    Lead Product(s): Durvalumab,Carboplatin,Paclitaxel,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Apices Soluciones

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 24, 2024

    blank

    10

    AstraZeneca

    United Kingdom
    arrow
    FNCE
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Durvalumab,Carboplatin,Paclitaxel,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Apices Soluciones

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed...

    Details : Durvalumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometrial Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    December 24, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATE SUPPLIERS

    read-more
    read-more

    01

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-Boc-Piperazine

    CAS Number : 57260-71-6

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropane carboxylic acid

    CAS Number : 1759-53-1

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropyl Carbonyl Chloride

    CAS Number : 4023-34-1

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    1-Cyclopropyl carbonyl piperazine

    CAS Number : 59878-57-8

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-FLUORO-5-FORMYL BENZONITRILE

    CAS Number : 218301-22-5

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-FLUORO-5-((4-OXO-3,4-DIHYDROPHTHALAZIN-1-YL) ME...

    CAS Number : 763114-26-7

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    DIMETHYL (3-OXO-1,3-DIHYDRO-2-BENZOFURAN-1-YL) PH...

    CAS Number : 61260-15-9

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CYCLOPROPANECARBONYL CHLORIDE

    CAS Number : 4023-34-1

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CYCLOPROPYL CARBONYL PIPERAZINE

    CAS Number : 59878-57-8

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Inventys

    India
    The MedTech Conference
    Not Confirmed
    arrow

    Inventys

    India
    The MedTech Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropane Carboxylic Acid

    CAS Number : 1759-53-1

    End Use API : Olaparib

    About The Company : INVENTYS Research Company – India’s Leading CDMO of Actives, Advanced Intermediates, and Specialty Chemicals. A research-driven Exclusive Synthesis and CDMO...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Olpha

    Latvia
    arrow
    CPhI WW Frankfurt
    Booth #3.0H20
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag Latvia
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olaparib

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength :

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olpha

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    AstraZeneca

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : DISCN

    Registration Country : USA

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : CAPSULE;ORAL

    Dosage Strength : 50MG

    Packaging :

    Approval Date : 2014-12-19

    Application Number : 206162

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    AstraZeneca

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 100MG

    Packaging :

    Approval Date : 2017-08-17

    Application Number : 208558

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    AstraZeneca

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 150MG

    Packaging :

    Approval Date : 2017-08-17

    Application Number : 208558

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    AstraZeneca

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Olaparib 50Mg 448 Unita' Oral Use

    Dosage Strength : 448 cps 50 mg vial

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    AstraZeneca

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Capsule, hard

    Dosage Strength : 50 mg

    Packaging : Bottle

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Cipla

    India
    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : USA

    OLAPARIB

    Brand Name : OLAPARIB

    Dosage Form : TABLET

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number : 219410

    Regulatory Info :

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Olon S.p.A

    Italy
    FNCE
    Not Confirmed
    arrow

    Olon S.p.A

    Italy
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Available Dossier- US-EU-RoW

    Registration Country : Italy

    Olaparib

    Brand Name :

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Available Dossier- US-EU-RoW

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    ASTRAZENECA

    United Kingdom
    The MedTech Conference
    Not Confirmed
    arrow

    ASTRAZENECA

    United Kingdom
    arrow
    The MedTech Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : CAPSULE;ORAL

    Dosage Strength : 50MG

    Approval Date : 2014-12-19

    Application Number : 206162

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ASTRAZENECA

    United Kingdom
    The MedTech Conference
    Not Confirmed
    arrow

    ASTRAZENECA

    United Kingdom
    arrow
    The MedTech Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 100MG

    Approval Date : 2017-08-17

    Application Number : 208558

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    ASTRAZENECA

    United Kingdom
    The MedTech Conference
    Not Confirmed
    arrow

    ASTRAZENECA

    United Kingdom
    arrow
    The MedTech Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 150MG

    Approval Date : 2017-08-17

    Application Number : 208558

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    05

    SANDOZ INC

    Switzerland
    The MedTech Conference
    Not Confirmed
    arrow

    SANDOZ INC

    Switzerland
    arrow
    The MedTech Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD :

    TE Code :

    OLAPARIB

    Brand Name : OLAPARIB

    Dosage Form : TABLET

    Dosage Strength : 150MG

    Approval Date :

    Application Number : 217936

    RX/OTC/DISCN :

    RLD :

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Europe

    read-more
    read-more

    01

    ASTRAZENECA AB

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    ASTRAZENECA AB

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Olaparib 50Mg 448 Unita' Oral Use

    Dosage Strength : 448 cps 50 mg vial

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    AstraZeneca AB (2)

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    AstraZeneca AB (2)

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Capsule, hard

    Dosage Strength : 50 mg

    Packaging : Bottle

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Astrazeneca Ab

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    Astrazeneca Ab

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Approved

    Registration Country : Sweden

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Approval Date : 08/05/2018

    Application Number : 20170407000065

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Astrazeneca Ab

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    Astrazeneca Ab

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Approved

    Registration Country : Sweden

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Film Coated Tablet

    Dosage Strength : 150mg

    Packaging :

    Approval Date : 08/05/2018

    Application Number : 20170407000072

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Astrazeneca Ab

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    Astrazeneca Ab

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Capsule

    Dosage Strength : 50mg

    Packaging :

    Approval Date : 16/12/2014

    Application Number : 20131002000126

    Regulatory Info : Deregistered

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Astrazeneca Ag

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    Astrazeneca Ag

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Olaparibum

    Brand Name : Lynparza

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Approval Date : 27/09/2018

    Application Number : 66745

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Astrazeneca Ag

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    Astrazeneca Ag

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Olaparibum

    Brand Name : Lynparza

    Dosage Form : Film Coated Tablet

    Dosage Strength : 150mg

    Packaging :

    Approval Date : 27/09/2018

    Application Number : 66745

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Astrazeneca Ab

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    Astrazeneca Ab

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Film Coated Tablet

    Dosage Strength : 150MG

    Packaging :

    Approval Date : 2018-05-28

    Application Number : 114959004

    Regulatory Info : Authorized

    Registration Country : Spain

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Astrazeneca Ab

    United Kingdom
    World Dairy Expo
    Not Confirmed
    arrow

    Astrazeneca Ab

    United Kingdom
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100MG

    Packaging :

    Approval Date : 2018-05-28

    Application Number : 114959002

    Regulatory Info : Authorized

    Registration Country : Spain

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Olon Spa

    Italy
    World Dairy Expo
    Not Confirmed
    arrow

    Olon Spa

    Italy
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Available Dossier- US-EU-RoW

    Registration Country : Italy

    Olaparib

    Brand Name :

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Available Dossier- US-EU-RoW

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Canada

    read-more
    read-more

    01

    ASTRAZENECA CANADA INC

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    ASTRAZENECA CANADA INC

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET

    Dosage Strength : 100MG

    Packaging : 60/120

    Approval Date :

    Application Number : 2475200

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ASTRAZENECA CANADA INC

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    ASTRAZENECA CANADA INC

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET

    Dosage Strength : 150MG

    Packaging : 60/120

    Approval Date :

    Application Number : 2475219

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Australia

    read-more
    read-more

    01

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    AstraZeneca Pty Ltd

    United Kingdom
    FNCE
    Not Confirmed
    arrow

    AstraZeneca Pty Ltd

    United Kingdom
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Dossiers

    read-more
    read-more

    01

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    01

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info : Lead Market Dossiers- Under De...

    Olaparib

    Dosage : Oral Solid Dosage Form

    Dosage Strength : 100MG

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info : Lead Market Dossiers- Under De...

    Olaparib

    Dosage : Oral Solid Dosage Form

    Dosage Strength : 150MG

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Olpha

    Latvia
    arrow
    CPhI WW Frankfurt
    Booth #3.0H20
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag Latvia
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olaparib

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength :

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olpha

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Olpha

    Latvia
    arrow
    CPhI WW Frankfurt
    Booth #3.0H20
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag Latvia
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info : Dossier Readiness:Q3 2026

    Olaparib

    Dosage : Tablet

    Dosage Strength :

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : Latvia

    Olpha

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Pinnacle Life Science

    India
    FNCE
    Not Confirmed
    arrow

    Pinnacle Life Science

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Olaparib

    Brand Name : Olaparib

    Dosage Form : Tablet

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Pinnacle Life Science

    India
    FNCE
    Not Confirmed
    arrow

    Pinnacle Life Science

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Olaparib

    Dosage : Tablet

    Dosage Strength : 100MG

    Brand Name : Olaparib

    Approval Date :

    Application Number :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Pinnacle Life Science

    India
    FNCE
    Not Confirmed
    arrow

    Pinnacle Life Science

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Olaparib

    Brand Name : Olaparib

    Dosage Form : Tablet

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Pinnacle Life Science

    India
    FNCE
    Not Confirmed
    arrow

    Pinnacle Life Science

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Olaparib

    Dosage : Tablet

    Dosage Strength : 150MG

    Brand Name : Olaparib

    Approval Date :

    Application Number :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    TherDose Pharma

    India
    FNCE
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Tablets

    Dosage Strength : 100mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    TherDose Pharma

    India
    FNCE
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Olaparib

    Dosage : Tablets

    Dosage Strength : 100mg

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    TherDose Pharma

    India
    FNCE
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Tablets

    Dosage Strength : 150mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    TherDose Pharma

    India
    FNCE
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    FNCE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Olaparib

    Dosage : Tablets

    Dosage Strength : 150mg

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 763113-22-0 / Olaparib API manufacturers, exporters & distributors?

    Olaparib manufacturers, exporters & distributors 1

    78

    PharmaCompass offers a list of Olaparib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olaparib manufacturer or Olaparib supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olaparib manufacturer or Olaparib supplier.

    PharmaCompass also assists you with knowing the Olaparib API Price utilized in the formulation of products. Olaparib API Price is not always fixed or binding as the Olaparib Price is obtained through a variety of data sources. The Olaparib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Olaparib

    Synonyms

    763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281

    Cas Number

    763113-22-0

    Unique Ingredient Identifier (UNII)

    WOH1JD9AR8

    About Olaparib

    Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Manufacturers

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one, including repackagers and relabelers. The FDA regulates 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Suppliers

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one supplier is an individual or a company that provides 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one active pharmaceutical ingredient (API) or 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one finished formulations upon request. The 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers may include 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API manufacturers, exporters, distributors and traders.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one DMF (Drug Master File) is a document detailing the whole manufacturing process of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one active pharmaceutical ingredient (API) in detail. Different forms of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one DMFs exist exist since differing nations have different regulations, such as 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one DMF submitted to regulatory agencies in the US is known as a USDMF. 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF includes data on 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with USDMF on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Drug Master File in Korea (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one. The MFDS reviews the 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF as part of the drug registration process and uses the information provided in the 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF to evaluate the safety and efficacy of the drug.

    After submitting a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with KDMF on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one WC

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one written confirmation (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one WC) is an official document issued by a regulatory agency to a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturer, verifying that the manufacturing facility of a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one APIs or 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one finished pharmaceutical products to another nation, regulatory agencies frequently require a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one WC (written confirmation) as part of the regulatory process.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with Written Confirmation (WC) on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with NDC on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP manufacturer or 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP API supplier for your needs.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA (Certificate of Analysis) is a formal document that attests to 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one's compliance with 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one specifications and serves as a tool for batch-level quality control.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA mostly includes findings from lab analyses of a specific batch. For each 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one may be tested according to a variety of international standards, such as European Pharmacopoeia (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one EP), 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one JP (Japanese Pharmacopeia) and the US Pharmacopoeia (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search